



# Ioana Alina Cristea University of Pavia, Italy Meta-Research Innovation Center at Stanford (METRICS), USA























# How Psychology deals with Open Science

Principles and practices
























**RESEARCH ARTICLE** 

# 

























# Open and reproducible science

- "Open science" (Munafó et al., 2017)
  - Making the content and process of producing evidence and claims transparent and accessible to others
- Reproducibility (Goodman, Fanelli & Ioannidis, 2016)
  - Methods
  - Results ("replication")
  - Inferential
























## Threats to reproducible science

nature human behaviour

#### A manifesto for reprod

Marcus R. Munafò<sup>1,2\*</sup>, Brian A. Nosek<sup>3,4</sup>, Doro Christopher D. Chambers<sup>7</sup>, Nathalie Percie du Jennifer J. Ware<sup>11</sup> and John P. A. Ioannidis<sup>12,13,1</sup>























Theme	Proposal	Examples of initiatives/potential solutions (extent of current adoption)	Stakeholder(s)
Methods	Protecting against cognitive biases	All of the initiatives listed below (* to ****) Blinding (**)	J, F
	Improving methodological training	Rigorous training in statistics and research methods for future researchers (*) Rigorous continuing education in statistics and methods for researchers (*)	I, F
	Independent methodological support	Involvement of methodologists in research (**) Independent oversight (*)	F
	Collaboration and team science	Multi-site studies/distributed data collection (*) Team-science consortia (*)	I, F

human behaviour

#### **PERSPECTIVE**

PUBLISHED: 10 JANUARY 2017 | VOLUME: 1 | ARTICLE NUMBER: 0021

OPEN

#### A manifesto for reproducible science

Marcus R. Munafò<sup>1,2\*</sup>, Brian A. Nosek<sup>3,4</sup>, Dorothy V. M. Bishop<sup>5</sup>, Katherine S. Button<sup>6</sup>, Christopher D. Chambers<sup>7</sup>, Nathalie Percie du Sert<sup>8</sup>, Uri Simonsohn<sup>9</sup>, Eric-Jan Wagenmakers<sup>10</sup>, Jennifer J. Ware<sup>11</sup> and John P. A. Ioannidis<sup>12,13,14</sup>

and non-financial

so on (\* to \*\*) J, F, R
als, \* for other studies)
ural sciences, J

ew, for example, Publons,

J, F

J, I, F

Transparency and Openness Promotion guidelines (\*)
Funding replication studies (\*)
Open science practices in hiring and promotion (\*)

Estimated extent of current adoption: \*, <5%; \*\*, 5–30%; \*\*\*, 30–60%; \*\*\*\*, >60%. Abbreviations for key stakeholders: J, journals/publishers; F, funders; I, institutions; R, regulators.























## Reporting and dissemination

- Prospective registration (clinical trials):
  - Public documentation of trial protocols before enrollment of 1<sup>st</sup> patient (ICMJE, 2005)
- Preregistration (psychology)
  - Declaring study plans (e.g., hypotheses, methods, and analyses) in a public registry before study commencement (Hardwicke & Wagenmakers, 2021)























### Preregistration

#### Evidentiary degrees of freedom

FITTING THE EVIDENCE TO THE HYPOTHESIS



#### Functions of preregistration

- Reduce bias by enabling resultsindependent research decisions
- Calibrate confidence by enabling an informed assessment of the risk of bias
- Bias reduction depends on how comprehensively decisions are specified in the preregistration
























# Evaluation of preregistration

- Trials of psychological interventions for depression with enrolment after ICMJE 2005 registration mandate
- 75/185 (40%) prospectively registered
  - 11/75 (15%) without specifying outcomes or assessment time points

- Studies with preregistered badges in *Psychological Science* 2015-2017
- 2/27 studies no deviation
- 1/27 disclosed all deviations



Miguel et al., 2021




















Claesen et al., 2021





### Registered reports

 Form of empirical publication in which study proposals are peerreviewed and pre-accepted <u>before</u> research is undertaken


























# Registered drug approval

- "Golden" approval pathway
- **Any trial** intended to support drug approval should be submitted as registered report



























# Evaluation of registered reports: transparency








# Evaluation of registered reports: quality









#### Incentives

- Badges to acknowledge open science practices (Center for Open Science)
  - Preregistration
  - Data sharing
  - Material sharing

Daniel Feiler, Johannes Müller-Trede

First Published January 21, 2022 Research Article https://doi.org/10.1177/09567976211032657













**PREREGISTERED** 



**MATERIALS** 






















## Evaluation of badges



- Randomized trial BMJ Open
- Information about data sharing policy
   + open data badge vs information
   alone
- Primary outcome: data sharing rate (N papers sharing/total N papers)
- 160 research articles
- Odds of awarding badges similar (OR= 0.9, 95% CI 0.1 to 9.01)
- 2 datasets shared in each group



















Kidwell et al., 2016; Farid et al., 2020





# New proposals: Discrepancy review

- Peer review intervention to reduce undisclosed discrepancies between registrations and publications
- Feasibility study for incorporating discrepancy review as a regular practice at journals and conducting a randomized trial

Box 1. Summary of the eight questions guiding the updated discrepancy review process.

- 1. Does the manuscript present only **exploratory** outcomes and analyses?
- 2. Is the registration **properly registered** (i.e., permanent and public)?
- 3. Does the registration date suggest that the timing of registration may be retrospective?
- 4. Are there discrepancies in the number, content, or prioritization of hypotheses?
- 5. Do the study arms, **independent variables**, exposure variables, or study/experimental grouping match?\*
- 6. Are there discrepancies in the number, content, or prioritization of outcome measures?
- 7. Do the analyses match?\*
- 8. While answering the previous questions, if you identified notable additional discrepancies or questionable research practices you may raise them. These could include sample size, control variables, covariates or moderators, eligibility criteria, analytic decisions (e.g., outlier definition), randomization, blinding, and data preprocessing, among others.\*

\*For these items, reviewers were instructed to not spend time looking for minor discrepancies.



















TARG meta-research group et al, 2022





# Thank you! Contact: <a href="mailto:loana.cristea@unipv.it">loana.cristea@unipv.it</a> Twitter: <a href="mailto:loana">loanaA</a> Cristea

















